                         SEQUENCE LISTING

<110>  PROYECTO DE BIOMEDICINA CIMA, S.L.
       DIGNA BIOTECH S.L.
       CONSEJO SUPERIOR DE INVESTIGACIONES CIENTFICAS
       UNIVERSIDAD PBLICA DE NAVARRA
 
<120>  IMMUNOGENIC COMPOSITIONS AND METHODS FOR THEIR USE

<130>  P6815PC00

<150>  EP11382065
<151>  2011-03-11

<160>  24    

<170>  PatentIn version 3.5

<210>  1
<211>  90
<212>  PRT
<213>  Homo sapiens

<400>  1

Asn Ile Asp Arg Pro Lys Gly Leu Ala Phe Thr Asp Val Asp Val Asp 
1               5                   10                  15      


Ser Ile Lys Ile Ala Trp Glu Ser Pro Gln Gly Gln Val Ser Arg Tyr 
            20                  25                  30          


Arg Val Thr Tyr Ser Ser Pro Glu Asp Gly Ile Arg Glu Leu Phe Pro 
        35                  40                  45              


Ala Pro Asp Gly Glu Asp Asp Thr Ala Glu Leu Gln Gly Leu Arg Pro 
    50                  55                  60                  


Gly Ser Glu Tyr Thr Val Ser Val Val Ala Leu His Asp Asp Met Glu 
65                  70                  75                  80  


Ser Gln Pro Leu Ile Gly Ile Gln Ser Thr 
                85                  90  


<210>  2
<211>  127
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  first member of the binding pair

<400>  2

Ala Glu Ala Gly Ile Thr Gly Thr Trp Tyr Asn Gln Leu Gly Ser Thr 
1               5                   10                  15      


Phe Ile Val Thr Ala Gly Ala Asp Gly Ala Leu Thr Gly Thr Tyr Glu 
            20                  25                  30          


Ser Ala Val Gly Asn Ala Glu Ser Arg Tyr Val Leu Thr Gly Arg Tyr 
        35                  40                  45              


Asp Ser Ala Pro Ala Thr Asp Gly Ser Gly Thr Ala Leu Gly Trp Thr 
    50                  55                  60                  


Val Ala Trp Lys Asn Asn Tyr Arg Asn Ala His Ser Ala Thr Thr Trp 
65                  70                  75                  80  


Ser Gly Gln Tyr Val Gly Gly Ala Glu Ala Arg Ile Asn Thr Gln Trp 
                85                  90                  95      


Leu Leu Thr Ser Gly Thr Thr Glu Ala Asn Ala Trp Lys Ser Thr Leu 
            100                 105                 110         


Val Gly His Asp Thr Phe Thr Lys Val Lys Pro Ser Ala Ala Ser 
        115                 120                 125         


<210>  3
<211>  226
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  fusion protein

<400>  3

Met Asn Ile Asp Arg Pro Lys Gly Leu Ala Phe Thr Asp Val Asp Val 
1               5                   10                  15      


Asp Ser Ile Lys Ile Ala Trp Glu Ser Pro Gln Gly Gln Val Ser Arg 
            20                  25                  30          


Tyr Arg Val Thr Tyr Ser Ser Pro Glu Asp Gly Ile Arg Glu Leu Phe 
        35                  40                  45              


Pro Ala Pro Asp Gly Glu Asp Asp Thr Ala Glu Leu Gln Gly Leu Arg 
    50                  55                  60                  


Pro Gly Ser Glu Tyr Thr Val Ser Val Val Ala Leu His Asp Asp Met 
65                  70                  75                  80  


Glu Ser Gln Pro Leu Ile Gly Ile Gln Ser Thr His Met Ala Glu Ala 
                85                  90                  95      


Gly Ile Thr Gly Thr Trp Tyr Asn Gln Leu Gly Ser Thr Phe Ile Val 
            100                 105                 110         


Thr Ala Gly Ala Asp Gly Ala Leu Thr Gly Thr Tyr Glu Ser Ala Val 
        115                 120                 125             


Gly Asn Ala Glu Ser Arg Tyr Val Leu Thr Gly Arg Tyr Asp Ser Ala 
    130                 135                 140                 


Pro Ala Thr Asp Gly Ser Gly Thr Ala Leu Gly Trp Thr Val Ala Trp 
145                 150                 155                 160 


Lys Asn Asn Tyr Arg Asn Ala His Ser Ala Thr Thr Trp Ser Gly Gln 
                165                 170                 175     


Tyr Val Gly Gly Ala Glu Ala Arg Ile Asn Thr Gln Trp Leu Leu Thr 
            180                 185                 190         


Ser Gly Thr Thr Glu Ala Asn Ala Trp Lys Ser Thr Leu Val Gly His 
        195                 200                 205             


Asp Thr Phe Thr Lys Val Lys Pro Ser Ala Ala Ser His His His His 
    210                 215                 220                 


His His 
225     


<210>  4
<211>  681
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  polynucleotide encoding the conjugate of the invention

<400>  4
atgaacattg atcgccctaa aggactggca ttcactgatg tggatgtcga ttccatcaaa       60

attgcttggg aaagcccaca ggggcaagtt tccaggtaca gggtgaccta ctcgagccct      120

gaggatggaa tccgggagct tttccctgca cctgatggtg aagacgacac tgcagagctg      180

cagggcctca ggccggggtc tgagtacaca gtcagtgtgg ttgccttgca cgatgatatg      240

gagagccagc ccctgattgg aatccagtcc acacatatgg ctgaagctgg tatcaccggc      300

acctggtaca accagctggg atccaccttc atcgttaccg ctggtgctga cggtgctctg      360

accggtacct acgaatccgc tgttggtaac gctgaatcta gatacgttct gaccggtcgt      420

tacgactccg ctccggctac cgacggttcc ggaaccgctc tgggttggac cgttgcttgg      480

aaaaacaact accgtaacgc tcactccgct accacctggt ctggccagta cgttggtggt      540

gctgaagctc gtatcaacac ccagtggttg ttgacctccg gcaccaccga agctaacgcg      600

tggaaatcca ccctggttgg tcacgacacc ttcaccaaag ttaaaccgtc cgctgcttcc      660

catcaccatc accaccatta a                                                681


<210>  5
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HLA-A2-restricted NS3 peptide derived from the hepatitis C NS3 
       protein, amino acids 1073-1081

<400>  5

Cys Val Asn Gly Val Cys Trp Thr Val 
1               5                   


<210>  6
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HPV E7 protein-derived antigenic peptide corresponding to amino 
       acids 1 to 29 of E7

<400>  6

Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln 
1               5                   10                  15      


Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn His 
            20                  25                  30  


<210>  7
<211>  56
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HPV E7 protein-derived antigenic peptide corresponding to amino 
       acids 43 to 98 of E7

<400>  7

Gly Gln Ala Glu Pro Asp Arg Ala His Tyr Asn Ile Val Thr Phe Cys 
1               5                   10                  15      


Cys Lys Cys Asp Ser Thr Leu Arg Leu Cys Val Gln Ser Thr His Val 
            20                  25                  30          


Asp Ile Arg Thr Leu Glu Asp Leu Leu Met Gly Thr Leu Gly Ile Val 
        35                  40                  45              


Cys Pro Ile Cys Ser Gln Lys Pro 
    50                  55      


<210>  8
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HPV E7 protein-derived antigenic peptide

<400>  8

Arg Ala His Tyr Asn Ile Val Thr Phe 
1               5                   


<210>  9
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TRP2-derived antigen 9

<400>  9

Ser Val Tyr Asp Phe Phe Val Trp Leu 
1               5                   


<210>  10
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TRP2-derived antigen 10

<400>  10

Thr Leu Asp Ser Gln Val Met Ser Leu 
1               5                   


<210>  11
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TRP2-derived antigen 11

<400>  11

Leu Leu Gly Pro Gly Arg Pro Tyr Arg 
1               5                   


<210>  12
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  tyrosinase-related protein 2 or TRP2-derived antigen 12

<400>  12

Leu Leu Gly Pro Gly Arg Pro Tyr Arg 
1               5                   


<210>  13
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TRP2-derived antigen 13

<400>  13

Ala Asn Asp Pro Ile Phe Val Val Leu 
1               5                   


<210>  14
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TRP2-derived antigen 14

<400>  14

Gln Cys Thr Glu Val Arg Ala Asp Thr Arg Pro Trp Ser Gly Pro 
1               5                   10                  15  


<210>  15
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TRP2-derived antigen 15

<400>  15

Ala Leu Pro Tyr Trp Asn Phe Ala Thr Gly 
1               5                   10  


<210>  16
<211>  199
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TRP2-derived antigen corresponding to amino acids 59 to 257 of 
       TRP2

<400>  16

Gly Gln Cys Thr Glu Val Arg Ala Asp Thr Arg Pro Trp Ser Gly Pro 
1               5                   10                  15      


Tyr Ile Leu Arg Asn Gln Asp Asp Arg Glu Leu Trp Pro Arg Lys Phe 
            20                  25                  30          


Phe His Arg Thr Cys Lys Cys Thr Gly Asn Phe Ala Gly Tyr Asn Cys 
        35                  40                  45              


Gly Asp Cys Lys Phe Gly Trp Thr Gly Pro Asn Cys Glu Arg Lys Lys 
    50                  55                  60                  


Pro Pro Val Ile Arg Gln Asn Ile His Ser Leu Ser Pro Gln Glu Arg 
65                  70                  75                  80  


Glu Gln Phe Leu Gly Ala Leu Asp Leu Ala Lys Lys Arg Val His Pro 
                85                  90                  95      


Asp Tyr Val Ile Thr Thr Gln His Trp Leu Gly Leu Leu Gly Pro Asn 
            100                 105                 110         


Gly Thr Gln Pro Gln Phe Ala Asn Cys Ser Val Tyr Asp Phe Phe Val 
        115                 120                 125             


Trp Leu His Tyr Tyr Ser Val Arg Asp Thr Leu Leu Gly Pro Gly Arg 
    130                 135                 140                 


Pro Tyr Arg Ala Ile Asp Phe Ser His Gln Gly Pro Ala Phe Val Thr 
145                 150                 155                 160 


Trp His Arg Tyr His Leu Leu Cys Leu Glu Arg Asp Leu Gln Arg Leu 
                165                 170                 175     


Ile Gly Asn Glu Ser Phe Ala Leu Pro Tyr Trp Asn Phe Ala Thr Gly 
            180                 185                 190         


Arg Asn Glu Cys Asp Val Cys 
        195                 


<210>  17
<211>  29
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Upper EDA-NdeI to amplify the extra domain A from fibronectin

<400>  17
catatgaaca ttgatcgccc taaaggact                                         29


<210>  18
<211>  30
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Lower EDA-NdeI oligonucleotide to amplify the extra domain A from
       fibronectin

<400>  18
catatgtgtg gactggattc caatcagggg                                        30


<210>  19
<211>  80
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  waal-Clo Fw: oligonucleotide designed and used to generate the 
       bacterial strains

<400>  19
tcaccagaac agaacctggc gaatttagat gccacaagcg tatttggaaa gattcattaa       60

gtgtaggctg gagctgcttc                                                   80


<210>  20
<211>  80
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  waal-Clo Rv: oligonucleotide designed and used to generate the 
       bacterial strains

<400>  20
agttgggaaa atgtagcgca gcgtttcgag gaacaaatga aaaactggtt tgataagtga       60

catatgaata tcctccttag                                                   80


<210>  21
<211>  25
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  GalE Fw: oligonucleotide designed and used to generate the 
       bacterial strains

<400>  21
gcggccgcat tcagcccctg caacg                                             25


<210>  22
<211>  22
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  GalE Rv: oligonucleotide designed and used to generate the 
       bacterial strains

<400>  22
ctcgaggccg ctacatgccc ga                                                22


<210>  23
<211>  24
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  GalM Fw: oligonucleotide designed and used to generate the 
       bacterial strains

<400>  23
ctcgagctcc gttaagccta tggt                                              24


<210>  24
<211>  24
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  GalM Rv: Oligonucleotide designed and used to generate the 
       bacterial strains

<400>  24
agatctaatc tggtgaccga caga                                              24


